New York lawmakers have passed landmark legislation targeting cannabis inversion, a practice that allows illicit products to enter the legal market. If signed by Governor Hochul, the bill would establish the nation’s first statutory framework to combat the issue.
Cannabis has officially entered Schedule III—but only partially. The DOJ’s 2026 move reshapes medical markets, research access, and federal recognition, while leaving recreational legality, interstate commerce, and full reform unresolved.
The Trump administration has officially moved cannabis to Schedule III, marking the most significant federal shift in decades. While it unlocks research and tax relief, it stops short of legalization—reshaping the industry in ways both promising and uncertain.
As cannabis markets mature, dispensaries are turning to AI-driven compliance and operational intelligence tools to navigate complex regulations while improving efficiency and profitability. Automation is rapidly becoming essential for retailers managing inventory, reporting, and financial oversight.
European cannabis laws are slowly catching up to long-standing culture as countries like Malta, Germany, Luxembourg, and Czechia move toward legalization. These reforms signal a major shift in policy, patient access, and adult use across Europe’s evolving cannabis landscape.
The federal reclassification of cannabis from Schedule I to Schedule III marks a historic shift in U.S. policy. Industry leaders weigh in on what rescheduling means for research, taxation, banking access, and the future of regulated cannabis.
The U.S. decision to reschedule cannabis to Schedule III signals federal recognition of medical value. Industry voices examine 280E tax relief, research access, patient impact, and the unresolved limits of reform.
President Donald Trump signs an Executive Order reclassifying cannabis from Schedule I to Schedule III, marking a major federal shift welcomed by the American Cannabis Collective and patient advocates.
Rumors suggest President Trump may reschedule marijuana from Schedule I to III. Industry leaders react with optimism and caution as the change could impact research, taxes, banking, and state policies, while critics warn of confusion and uneven effects for small businesses.
Governor Kathy Hochul demands resignations of two top New York cannabis regulators following mishandled investigations and regulatory missteps. With adult-use sales booming, the state aims to restore accountability and strengthen leadership at the Office of Cannabis Management.
Grow City CZ founder Michal Otipka has spent nearly 30 years building Europe’s most influential grow shop. From police raids to legalization, discover how his Prague-based “permanent exhibition” is reshaping home cultivation across the continent.
Congress’s 2025 spending bill includes a sweeping change to federal hemp law, redefining legal hemp and effectively banning most hemp-derived THC products. Industry leaders warn the move could “wipe out” 95% of the market, while advocates say it underscores the need for unified cannabis regulation.
Tobacco giants are investing heavily in cannabis, from R&D partnerships to vapor technology and wellness products. As integration accelerates, the focus shifts from resistance to direction—how to merge corporate infrastructure with the plant’s creative and cultural foundations.
Germany’s Cannabis Act evaluation shows fewer youth consumers, no rise in accidents, and declining crime. Bloomwell CEO Niklas Kouparanis warns against restricting medical access, arguing it would re-criminalize patients and undermine public health progress.
How will cannabis advertising change if the plant moves to Schedule III? From 280E relief to FDA oversight, discover what rescheduling means for marketing, media access, and how culture-driven brands can stay ahead.
